ClinConnect ClinConnect Logo
Search / Trial NCT02189798

Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness

Launched by ADVANCED BIONICS · Jul 11, 2014

Trial Information

Current as of May 27, 2025

Terminated

Keywords

Cochlear Implant Hi Res™ 90 K Advantage Implant Cochlear Implantation Hi Focus™ Mid Scala Electrode Listening Benefits Adults Cochlear Implant Benefit Electrical Stimulation Electro Acoustic Stimulation (Eas)

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion criteria: Newly Implanted Group:
  • Ability to provide informed consent
  • No previous cochlear implant experience in either ear
  • 18 years of age or older
  • Up to a moderate sensorineural hearing loss in the low-to-mid frequencies (pure tone average ≤65 dB for 125, 250, 500, and 1000 Hz) and a severe-to-profound sensorineural hearing loss in the high frequencies (pure tone average ≥ 70 dB HL for 2,000, 3000, 4,000, and 8,000 Hz) in the ear to be implanted
  • Aided CNC word recognition score up to 50% in ear to be implanted
  • Up to a moderate sensorineural hearing loss in the low-to-mid frequencies (pure tone average ≤65 dB for 125, 250, 500, and 1000 Hz) and a severe-to-profound sensorineural hearing loss in the high frequencies (pure tone average ≥ 70 dB HL for 2,000, 3000, 4,000, and 8,000 Hz) in the contralateral (non-implanted) ear
  • Aided CNC word recognition score up to 80% in the contralateral ear
  • English language proficiency
  • Willingness to use an ear-level sound processor postoperatively for the duration of the study trial
  • Willingness to participate in all scheduled procedures outlined in the protocol
  • Exclusion Criteria: Newly Implanted Group:
  • Preoperative audiometric conductive overlay of 15 dB or greater at two frequencies or more in range of 500-1000 Hz in the ear to be implanted
  • Congenital hearing loss (for purpose of this study, onset prior to age 2 years\*). \*Based on critical period for speech and language development
  • Duration greater than 30 years of severe-to-profound high-frequency hearing loss
  • Cochlear malformation or obstruction that would preclude full insertion of electrode array in the ear to be implanted
  • Medical or psychological conditions that contraindicate surgery or impact the ability to manage an implanted device or the study related procedures as determined by the investigator
  • Deafness due to central auditory lesion or cochlear nerve deficiency, diagnosis of auditory neuropathy/dys-synchrony in either the ear to be implanted or the contralateral ear
  • Active middle-ear disease/infection in the ear to be implanted
  • Unrealistic expectations regarding potential benefits, risks and limitations inherent to implant surgical procedures as determined by the investigator
  • Unwillingness or inability of subject to comply with all investigational requirements as determined by the investigator
  • EAS Fitting Inclusion Criteria: Newly Implanted and Existing Implanted Groups
  • Ability to provide informed consent
  • 18 years of age or older, unilaterally implanted with HiRes90K™ Advantage cochlear implant with HiFocus™ Mid-Scala electrode and fit with an ear-level sound processor (i.e. Naída family device)
  • Postoperative unaided low frequency audiometric hearing thresholds in the treated ear up to 80 dB HL for at least one frequency from 125 - 1000 Hz
  • English Language Proficiency
  • Willingness to participate in all scheduled procedures outlined in the study protocol
  • EAS Fitting Exclusion Criteria: Newly Implanted and Existing Implanted Groups
  • Unilaterally implanted with HiRes 90K™ Advantage cochlear implant with HiFocus™ Helix® and HiFocus™ 1j electrode
  • Exclusive use of a body worn external sound processor
  • Deafness due to central auditory lesion or cochlear nerve deficiency, diagnosis of auditory neuropathy/dys-synchrony in either the implanted or the contralateral ear
  • Postoperative unaided low frequency audiometric hearing thresholds in the treated ear exceeding 80 dB HL at each frequency from 125 - 1000 Hz Unwillingness or inability of subject to comply with all investigational requirements as determined by the investigator

About Advanced Bionics

Advanced Bionics is a global leader in the development of innovative cochlear implant technology and hearing solutions. Committed to improving the quality of life for individuals with hearing loss, the company combines cutting-edge research with advanced engineering to create devices that enhance auditory experiences. Advanced Bionics actively sponsors clinical trials to evaluate the safety and efficacy of its products, ensuring they meet the highest standards of performance and patient satisfaction. With a focus on collaboration and innovation, the company strives to advance the field of auditory technology and provide transformative solutions for patients worldwide.

Locations

Rochester, Minnesota, United States

New York, New York, United States

Saint Louis, Missouri, United States

Lexington, Kentucky, United States

Tampa, Florida, United States

Columbia, Missouri, United States

Washington, District Of Columbia, United States

Nashville, Tennessee, United States

Saint Louis, Missouri, United States

Oklahoma City, Oklahoma, United States

Austin, Texas, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials